The Microdroplet LiftDr. Kenneth Steinsapir reveals his patented botulinum toxin delivery method that minimizes brow activity without treating the forehead.
Toxin vs toxin: How do you choose?Botox, Dysport and Xeomin may share similarities, but several factors can affect the best way to choose which is best for your individual patients.
Botox, Dysport, Xeomin not interchangeableStudy shows “accepted” equivalents of neurotoxin treatment dosages do not deliver comparable results.
Neurotoxin pipeline advances, stay wary of counterfeitsAs the neurotoxin market is set for expansion, so expands the market of counterfeit products. One expert reviews the innovative options coming up through the pipeline and cautions colleagues about the risks associated with counterfeits.
Top 5 dermatology controversiesThere are five controversies rattling today’s dermatology community, causing some dermatologists to think twice about commonly used products, services and procedures.
Xeomin vs Botox: Head-to-head study resultsThis is the first randomized, prospective, double-blinded, parallel-group study to compare the neurotoxins head to head.
Best practices for neurotoxinsDr. Corey Maas provides insight into new neuromodulators currently seeking FDA approval at this year's Global Aesthetic Conference.
A better botulinum toxin?A topical neuromodulator in development appears to last longer than currently available products when the topical formulation is injected intramuscularly, an expert says.
Reconstitution is key to optimizing neurotoxin results
Reconstitution is key to optimizing neurotoxin resultsSuboptimal reconstitution of botulinum toxin type A preparations can diminish the efficacy of neuromodulators for cosmetic use.
VIDEO: Aesthetic procedures on upward trendIf your practice’s business is anything like national trends, you may need to beef-up your number of staff members for 2014 to handle the explosion of aesthetic procedures coming through your doors.